PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 4 | 2 | A76-82
Article title

58-year-old woman with pancreatic neuroendocrine tumour

Content
Title variants
Languages of publication
EN
Abstracts
EN
We reported a 58-year-old woman with tumor in the tail and body of pancreas measuring 70 mm in diameter who underwent distal pancreatectomy and splenectomy. Examination of a specimen of the pancreatic mass obtained histopathological features of a well-differentiated neuroendocrine carcinoma (WHO 2000 r. NECLM group 2, MIB < 2%). Immunohistochemical staining showed that the tumor cells were positive for chromogranin and synaptophysin. The tumor was radical resected; there were 9 lymph nodes without metastases. The patient was attending routine follow-up 3 years after resection, when ultrasonography detected hepatic tumor with a low echoic area, confirmed as at least 3 lesions in CT. The patient presented with symptoms of general malaise, anorexia, weight loss, diarrhea, and diabetes mellitus. The diagnosis including of the histopathological features resected specimen and symptoms suggested a somatostatinoma. The patient denied the surgery treatment so she was treated with good clinical and biochemical (normalization of chromogranin A) response to octreotide LAR. During follow-up 4 months after, Computer Tomography showed progression. The patient refused suggested chemotherapy streptozotocin combined with doxorubicin. We continued treatment with octreotide LAR, taking into consideration lack of symptoms and stabilization in chromogranin A level, with good result and stabilization in following Computer Tomography. Somatostatinoma originates from delta cells and is a rare neoplasm, accounting for about 1% of gastroenteropancreatic endocrine neoplasms. About half of somatostatinomas originate in the pancreas, and the remainders originate in other parts of the gastrointestinal tract, mainly in the duodenum. Measurement of the plasma somatostatin concentration is useful for making a diagnosis of somatostatinoma, however is very difficult to perform this examination in our country. Successful treatment with long-acting somatostatin analogues (octreotide LAR) has been reported after progression.
Discipline
Publisher

Journal
Year
Volume
4
Issue
2
Pages
A76-82
Physical description
Contributors
  • Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland
References
  • Kos-Kudła B, Bolanowski M, Handkiewicz-Junak D et al. Zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych). Endokrynol Pol 2008; 59: 41-56.
  • Cwikla JB, Królicki L, Buscombe JR et al. Diagnostyka obrazowa guzów neuroendokrynnych. Onkol w Praktyce Klin 2006; 1: 18-31.
  • Pavel M, Baudin E, Couvelard A et al. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinology 2012; 95: 157–176.
  • Plöckinger U, Rindi R, Arnold R et al. Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours. Neuroendocrinology 2004; 80: 394-424.
  • Rinke A, Muller HH, Schade–Brittinger C et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group, JCO, 2009; 27: 4656-4663.
  • Moertel CG, Lefkopoulo M, Lipsitz S et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-23.
  • Öberg K. Management of neuroendocrine tumours. Ann Oncol 2004; (suppl 4): 293-8.
  • O’Toole D, Hentic O, Corcos O et al. Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 2004; 80(suppl 1): 79-84.
  • Yao JC, Shah MH, Ito T et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
  • Garbrecht N, Anlauf M, Schmitt A et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocrine-Related Cancer 2008: 15; 229-241.
  • Harris GJ, Tio F, Cruz AB Jr. Somatostatinoma: a case report and review of the literature. J Surg Oncol 1987; 36: 8-16.
  • Vinik AI, Strodel WE, Eckhauser FE et al. Somatostatinomas, PPomas, neurotensinomas. Semin Oncol 1987; 14: 263-81.
  • Konomi K, Chijiiwa K, Katsuta T et al. Pancreatic somatostatinoma: a case report and review of the literature. J Surg Oncol 1990; 43: 259-65.
  • Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18: 13-22.
Document Type
report
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-49ce8908-fce0-4c32-9802-34a756ff74ad
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.